These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 33785384)
1. Nonavalent human papilloma virus vaccine for the treatment of multiple recalcitrant warts: An open-label study. Shin JO; Son JH; Lee J; Kim HS; Ko HC; Kim BS; Kim MB; Shin K J Am Acad Dermatol; 2022 Apr; 86(4):940-941. PubMed ID: 33785384 [No Abstract] [Full Text] [Related]
2. Efficacy of nonavalent human papillomavirus vaccine for recalcitrant warts. Dianzani C; Neagu N; Venuti A; Coscarella G; DE Franciscis B; Montini F; Zalaudek I; Conforti C Ital J Dermatol Venerol; 2023 Feb; 158(1):67-68. PubMed ID: 36939508 [No Abstract] [Full Text] [Related]
3. Nonavalent human papillomavirus vaccination as alternative treatment for genital warts. Bossart S; Gabutti MP; Seyed Jafari SM; Hunger RE Dermatol Ther; 2020 Jul; 33(4):e13771. PubMed ID: 32500585 [TBL] [Abstract][Full Text] [Related]
4. Recalcitrant cutaneous warts treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, and 18) in a developmentally delayed, 31-year-old white man. Venugopal SS; Murrell DF Arch Dermatol; 2010 May; 146(5):475-7. PubMed ID: 20479293 [No Abstract] [Full Text] [Related]
5. [HPV vaccination with quadrivalent or nonavalent vaccine: an opportunity to eliminate genital warts as well]. van Bergen JEAM Ned Tijdschr Geneeskd; 2020 Jan; 164():. PubMed ID: 32073799 [TBL] [Abstract][Full Text] [Related]
6. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis. Tay SK; Hsu TY; Pavelyev A; Walia A; Kulkarni AS BJOG; 2018 Mar; 125(4):478-486. PubMed ID: 29266694 [TBL] [Abstract][Full Text] [Related]
7. Quadrivalent human papilloma virus vaccine for the treatment of multiple warts: a retrospective analysis of 30 patients. Yang MY; Son JH; Kim GW; Kim HS; Ko HC; Kim MB; Lim KM; Kim BS J Dermatolog Treat; 2019 Jun; 30(4):405-409. PubMed ID: 30232912 [No Abstract] [Full Text] [Related]
8. Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations. Bosco L; Serra N; Fasciana T; Pistoia D; Vella M; Di Gregorio L; Schillaci R; Perino A; Calagna G; Firenze A; Capra G Sci Rep; 2021 Feb; 11(1):4096. PubMed ID: 33603082 [TBL] [Abstract][Full Text] [Related]
9. HPV Vaccine for Treatment of Recalcitrant Cutaneous Warts in Adults: A Retrospective Cohort Study. Waldman A; Whiting D; Rani M; Alam M Dermatol Surg; 2019 Dec; 45(12):1739-1741. PubMed ID: 31765341 [No Abstract] [Full Text] [Related]
10. Human papillomavirus vaccination update: Nonavalent vaccine and the two-dose schedule. Brotherton JM Aust J Gen Pract; 2018 Jul; 47(7):417-421. PubMed ID: 30114867 [TBL] [Abstract][Full Text] [Related]
11. Clearance of genital warts in a pediatric patient following administration of the nonavalent human papillomavirus vaccine. Couselo-Rodríguez C; Pérez-Feal P; Alarcón-Pérez CE; Bou-Boluda L; Baselga E Int J Dermatol; 2021 Sep; 60(9):e377-e379. PubMed ID: 33825183 [No Abstract] [Full Text] [Related]
12. [Viral warts on hands and feet are often self-limiting]. Nordentoft EL; Waldorf FB Ugeskr Laeger; 2013 May; 175(22):1559-61. PubMed ID: 23721839 [TBL] [Abstract][Full Text] [Related]
13. The Quadrivalent Human Papillomavirus Vaccine in Recalcitrant Non-genital Warts: A Retrospective Study. Kuan LY; Chua SH; Pan JY; Yew YW; Tan WP Ann Acad Med Singap; 2020 Oct; 49(10):749-755. PubMed ID: 33283838 [TBL] [Abstract][Full Text] [Related]
14. Three cases of recalcitrant cutaneous warts treated with quadrivalent human papillomavirus (HPV) vaccine: the HPV type may not determine the outcome. Hayashi A; Matsumoto K; Mitsuishi T Br J Dermatol; 2020 May; 182(5):1285-1287. PubMed ID: 31675436 [No Abstract] [Full Text] [Related]
16. Human papilloma virus vaccine for palmoplantar warts: A retrospective study of 18 patients. Merio L; Chanal J; Jachiet M; Pourcher V; Arnault JP; Jouhet C; Milpied-Homsi B; Bourgault-Villada I; Aubin F; Caux F; Fouéré S; Vicaut E; Beylot-Barry M; Chosidow O; J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):e223-e225. PubMed ID: 35972053 [No Abstract] [Full Text] [Related]
17. Nonavalent human papillomavirus vaccine for cutaneous warts: a retrospective study. Shin MK; Seo JI Eur J Dermatol; 2022 Sep; 32(5):642-643. PubMed ID: 36468725 [No Abstract] [Full Text] [Related]
18. Combined bivalent human papillomavirus vaccine and Candida antigen versus Candida antigen alone in the treatment of recalcitrant warts. Marei A; Nofal A; Alakad R; Abdel-Hady A J Cosmet Dermatol; 2020 Mar; 19(3):758-762. PubMed ID: 31328869 [TBL] [Abstract][Full Text] [Related]
19. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Chatterjee A Expert Rev Vaccines; 2014 Nov; 13(11):1279-90. PubMed ID: 25256262 [TBL] [Abstract][Full Text] [Related]
20. Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure. Lurie S; Mizrachi Y; Chodick G; Katz R; Schejter E Gynecol Oncol; 2017 Aug; 146(2):299-304. PubMed ID: 28602548 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]